Syneos Health downgraded by Evercore ISI with a new price target

11/7/22 9:27:28 AM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Evercore ISI downgraded Syneos Health from Outperform to In-line and set a new price target of $27.00 from $55.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SYNH

Date	Price Target	Rating	Analyst
2/13/2023	$30.00 → $28.00	Neutral → Underweight	JP Morgan
1/17/2023	$30.00 → $25.00	Overweight → Underweight	Barclays
1/13/2023	$25.00	Overweight → Underweight	Barclays
12/14/2022	$66.00 → $38.00	Buy → Neutral	Mizuho
11/7/2022	$55.00 → $27.00	Outperform → In-line	Evercore ISI
10/18/2022	$85.00 → $53.00	Overweight → Neutral	JP Morgan
9/14/2022		Buy → Neutral	Guggenheim
9/7/2022	$68.00	Neutral	UBS